1768 CABG patients had purchased lipid-modifying agents during the three years before, and 94.9% and 96.8% during the year after the procedure, respectively. Beta blocking agents were purchased by 84.9% of PCI patients before and by 87.9% after the procedure, and by 86.3% of CABG patients before and 97.1% after the operation. In CABG patients the purchase of organic long acting nitrates fell from 59.7% before to 10.1% after the operation but remained almost constant in PCI patients (64.3% vs. 54.4%). Use of ADP receptor blocking agents increased in PCI patients from the preintervention 26.3% to the post-intervention 83.9%. Greater use of hospital services before and after the interventions had an incremental effect on medication purchases. ConClusions: Based on information on drug purchases, real-world use of recommended pharmacological therapy before and after revascularization complied both in PCI and CABG patients surprisingly well with current guidelines.

No abstract